OS Therapies Reports Third Quarter 2024 Financial Results and ...

Purple Biotech Reports Third Quarter 2024 Financial Results

("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune ...

AMD Reports Third Quarter 2024 Financial Results

On a non-GAAP(*) basis, gross margin was 54%, operating income was $1.7 billion, net income was $1.5 billion and diluted earnings per share was ...

BD Reports Third Quarter Fiscal 2024 Financial Results

MediaRoom ; Adjusted Revenues. ~$20.1 to $20.2 billion. n/a ; Organic Revenue Growth (FXN). 5.0% to 5.25%. 5.5% to 6.25% ; Adjusted Diluted EPS.

Lantern Pharma Reports Third Quarter 2024 Financial Results and ...

R&D Expenses: Research and development expenses were approximately $3.7 million for the quarter ended September 30, 2024, compared to ...

Leap Therapeutics Reports Third Quarter 2020 Financial Results

PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, ...

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial ...

Research and development expenses for the three months ended August 31, 2024, were $55.5 million compared with $47.9 million for the three months ended August ...

Lantheus Reports Third Quarter 2024 Financial Results

Worldwide revenue increased 18.4% to $378.7 million compared to the same period in 2023. Sales of PYLARIFY were $259.8 million , an increase of ...

Surf Air Mobility Reports Third Quarter Financial Results, Exceeding ...

Revenue of $28.4 million for the third quarter 2024 as compared to $28.9 million for the same period of the prior year on a pro-forma basis, ...

RenovoRx Reports Third Quarter 2024 Financial Results and ...

R&D Expenses: Research and development expenses were approximately $1.7 million for the three months ended September 30, 2024, remaining flat ...

IO Biotech Reports Third Quarter 2024 Financial Results and ...

Cash and cash equivalents as of September 30, 2024 were $80.2 million, compared to $143.2 million at December 31, 2023. During the three months ...

Meta Reports Third Quarter 2024 Results

Revenue – Total revenue was $40.59 billion, an increase of 19% year-over-year. Revenue on a constant currency basis would have increased 20% ...

Sage Therapeutics to Report Third Quarter 2024 Financial Results ...

Investors & Media · Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024.

Merck Announces Third-Quarter 2024 Financial Results

For the third quarter of 2024, Generally Accepted Accounting Principles (GAAP) earnings per share (EPS) assuming dilution was $1.24 and non-GAAP ...

Regeneron Reports Third Quarter 2024 Financial and ... - Public now

... treatment of iron overload in patients with beta-thalassemia was initiated. Third Quarter 2024 Financial Results. Revenues. ($ in millions). Q3 2024. Q3 2023.

BioNTech Announces Third Quarter 2024 Financial Results and ...

Revenues reported were €1,244.8 million for the three months ended September 30, 2024, compared to €895.3 million for the comparative prior year ...

Moderna Reports Third Quarter 2024 Financial Results and ...

Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03. Achieves year-to-date product sales of $2.2 billion; ...

Recursion Provides Business Updates and Reports Third Quarter ...

Revenue: Total revenue was $26.1 million for the third quarter of 2024, compared to $10.5 million for the third quarter of 2023. The increase ...

Xencor Reports Third Quarter 2024 Financial Results

Xencor Reports Third Quarter 2024 Financial Results · $10.7 million , compared to · $59.2 million for the same period in 2023.

Jazz Pharmaceuticals Announces Third Quarter 2024 Financial ...

Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results · $1.05 billion and a 14% year-over-year increase in revenue from our key ...

ALX Oncology Reports Third Quarter 2024 Financial Results and ...

These expenses for the three months ended September 30, 2024, were $26.5 million, compared to $45.8 million for the prior-year period. R&D ...